Accueil
Bourse
Actions Paris

Consensus des Analystes Sanofi

Cotation du 24/09/2021 à 17h35 Sanofi -1,01% 82,020€

Objectif de cours au 25/09/2021

104,656 €
Potentiel de +28%
cours actuel 82,020€

Note médiane des 26 analystes

2,1
5 Vendre 4 Alléger 3 Conserver 2 Renforcer 1 Acheter

Evolution des recommandations

Recommandations 25/09/2020 25/12/2020 25/03/2021 25/06/2021 25/09/2021
Acheter 12 10 11 10 9
Renforcer 6 8 7 8 7
Conserver 7 9 7 7 9
Alléger - - - - -
Vendre - - 1 1 1
Nb d'analystes 25 27 26 26 26
Note Médiane 1,80 1,96 1,96 2,00 2,12
Historique des objectifs 105,537€ 103,352€ 100,608€ 101,746€ 104,656€

Prévisions

2020 2021 2022
Chiffre d'affaires 36 041,00 37 414,95 39 558,97
EBITDA 11 443,00 11 556,82 12 812,52
EBIT 9 762,00 10 448,22 11 665,63
Résultat Net 12 314,00 6 045,78 7 137,11
Flux de trésorerie disponible 6 982,00 6 594,16 8 005,63
Dette nette 8 789,00 7 877,91 4 042,24
PER 14,00 12,93 11,51
Copyright ©2021, S&P Global Market Intelligence. Reproduction of CIQ Estimates in any form is prohibited except with the prior written permission of S&P Global Market Intelligence. CIQ Estimates are not investment advice and a reference to a particular investment or security, a credit rating or any observation concerning a security or investment provided in CIQ Estimates is not a recommendation to buy, sell or hold such investment or security or make any other investment decisions. S&P Global Market Intelligence, its affiliates and their third-party providers (together, “S&P Global”) do not guarantee the accuracy, adequacy, completeness or availability of any information and are not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P GLOBAL DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P Global be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of CIQ Estimates.

Actualités Sanofi

Plus d'actualités